Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just took profits on HEB $4.42, OSCI $0.50, GNBT $0.97, and looking for a little higher on CEGE. (I ALWAYS sell too early, but I'm up 100%++ on all and am leaving on a trip tomorrow for the week).
Only Bio-Tech I have left is DVAX which retraced nicely yesterday. Looking for another push past $2.00 there. Should move with the others today.
Watch for CEGE presentation
In yesterday with tech breakout :)
CEGE chart--nice breakout volume....would have been nice to see a close at the HOD
CEGE MAJOR breakout at .72
$0.49's getting hit already which is nice! Up 8.89% so far! MA 50 held, so Let's get this back to $0.64ish!
Yesterday was the first day I followed this, but it looks like we held the 50MA yesterday at $0.45. Be nice to see us trend up now.
hope you're right.
I'm afraid that CEGE is being heavy shorted at the moment. Huge volume, continious declining and tradings below 50 days of moving average....
LOL, oh well. Didn't work out today, but I think the 20,000 at $0.54 was a good buy with all the HUGE insider buys at that price range recently. Just some profit taking. Would have been nice to wait and scoop at $0.45-$0.46 range, but I still think this will provide a healthy profit for me.
when do they normaly wake up?
Not bad at all! Have a feeling we push through $0.60 again once the west coast wakes up!
In the past month Insiders have purchased the following:
150,000 Shares Bought at $0.55
150,000 Shares Bought at $0.57
400,000 Shares Bought between $0.62-$0.80
400,000 Shares Bought at $0.63
400,000 Shares Bought between $0.59-$0.61
400,000 Shares Bought Between $0.49-$0.63
200,000 Shares Bought at $0.50
Another 1.4M shares purchased at various prices.
Just picked up my FIRST 20,000 at $0.54. Saving Powder for more just in case!
I've been noticing them for months .
Have you noticed these INSIDER BUYS recently?!?!?!
The market really likes the news !! EOM .
Ceregene news : ( CEGE is a partner with Ceregene )
Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
On Wednesday May 27, 2009, 7:00 am EDT
SAN DIEGO, May 27 /PRNewswire/ -- Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. CERE-120 uses AAV-based gene therapy to deliver the neurotrophic factor, neurturin, to Parkinson's disease patients in order to restore the function and protect degenerating nigrostriatal neurons. The company previously announced that the Phase 2 trial did not meet its primary endpoint of improvement in the Unified Parkinson's Disease Rating Scale (UPDRS) motor off score at 12 months of follow-up, although several secondary endpoints suggested a modest clinical benefit.
The additional, protocol-prescribed analyses reported today focused on further analyses of the data from the 30 subjects who continued to be evaluated under double-blind conditions for up to 18 months which indicate increasing effects of CERE-120 over time. A clinically modest but statistically significant treatment effect in the primary efficacy measure (UPDRS motor off; p=0.025), as well as similar effects on several more secondary motor measures (p<0.05), were seen at the 18 month endpoint. Not a single measure similarly favored sham surgery at either the 12 month or 18 month time points. Additionally, CERE-120 appears safe when administered to advanced Parkinson's disease patients, with no significant concerns related to the neurosurgical procedure, the gene therapy vector, or the expression of neurturin in the Parkinson's disease brain.
The company also reported the results of analyses of neurturin gene expression in the brains from two CERE-120 treated subjects who died of causes unrelated to treatment. These analyses revealed that CERE-120 produced clear evidence of neurturin expression in the targeted putamen but no evidence for transport of this protein to the cell bodies of the degenerating neurons, located in the substantia nigra. In addition to the known cell loss in Parkinson's disease, these findings suggest that deficient axonal transport in degenerating nigrostriatal neurons in advanced Parkinson's disease impaired transport of CERE-120 and/or neurturin from putaminal terminals to nigral cell bodies, reducing the bioactivity of CERE-120. The data were presented today at the American Society of Gene Therapy Meeting in San Diego, CA by Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer.
"While we were disappointed that our initial analysis of the data from this trial did not demonstrate a benefit of CERE-120 in the primary endpoint at 12 months, we are greatly encouraged by both the results of these protocol-prescribed analyses in patients who remained blinded for up to 18 months, as well as by the insight we gained," stated Dr. Bartus. "Collectively, these data suggest that CERE-120 is indeed exerting a unique and potentially important biological effect on the degenerating dopamine neurons in moderately advanced Parkinson's disease patients but that the inability of these neurons to efficiently transport neurturin back to their cell bodies compromises and delays the neurotrophic effects of neurturin in a manner that had not been anticipated. Importantly, we believe that we can overcome the transport problems of these degenerating neurons by modifying the dosing paradigm to also directly target their cell bodies in the substantia nigra with CERE-120."
"We remain optimistic that CERE-120 has the potential to significantly improve the treatment of advanced Parkinson's disease patients," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "The information gained from this initial controlled Phase 2 trial in advanced Parkinson's disease patients has been invaluable, and we can now incorporate these insights in a follow-on clinical trial that we are planning to initiate later this year. Our goal remains to significantly improve the symptoms of Parkinson's patients and also to provide the opportunity to delay further disease progression."
About Phase 2 Trial of CERE-120
Ceregene's Phase 2 trial was a double-blind, controlled clinical trial that completed enrollment of 58 patients with advanced Parkinson's disease in October 2007. This study was launched after successful execution of an extensive nonclinical program and preliminary evidence of safety and efficacy in advanced Parkinson's patients via an open-label Phase 1 trial in 12 patients. Patients in the Phase 2 trial were enrolled across nine leading academic medical centers in the United States, with two thirds of patients receiving CERE-120 and one third enrolled into a control group. Patients received a single administration of CERE-120 via stereotactic neurosurgery to deliver the drug into the putamen region of the brain and were followed for a minimum of 12 months for safety and efficacy, with over half the subjects followed for 15 to 18 months under blinded conditions, allowing longer-term analyses of the therapeutic effects of CERE-120. Ceregene gratefully acknowledges the financial support received from the Michael J. Fox Foundation for Parkinson's Research to help defray some of the costs of the CERE-120 Phase 1 and Phase 2 clinical trials.
About CERE-120 and its Application to Treating Parkinson's Disease
CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin, a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and restoring normal function. Neurturin is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease. Degeneration of these neurons is responsible for the major motor impairments of Parkinson's disease. CERE-120 has been delivered by stereotactic injection to the terminal fields (i.e., the ends of the degenerating neurons), located in an area of the brain called the putamen. The cell bodies for these same neurons are located in a different area of the brain, called the substantia nigra. Once CERE-120 is delivered to the brain, it provides stable, long-lasting expression of neurturin in a highly targeted fashion. Genzyme Corporation (Nasdaq: GENZ - News) has licensed the ex-North American rights for the development and commercialization of CERE-120 from Ceregene, an agreement that was announced in June 2007.
About Parkinson's Disease
Parkinson's disease is a progressive movement disorder that affects a million people in the United States. Its main symptoms, stiffness, tremors and slowed movements and gait, are caused by a loss of dopamine-containing nerve cells in the substantia nigra, which project their axons to the putamen. Dopamine is a neurotransmitter involved in controlling movement and coordination, so Parkinson's patients exhibit a progressive inability to initiate and control physical movements. There is currently no treatment that can reverse the degeneration of these neurons, let alone cure Parkinson's disease.
About Ceregene
Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth (neurotrophic) factors for the treatment of neurodegenerative and retinal disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in a multi-center, controlled Phase 2 study for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE - News) as well as Hamilton BioVentures and California Technology Partners.
Contacts: Jeffrey M. Ostrove, Ph.D.
President and CEO
Ceregene, Inc.
(858) 458-8808
Friday news :
Cell Genesys Commences Exchange Offer for $68.3 million Convertible Notes
Holder of Approximately 67.6% of the Notes Has Committed to Tender its Notes in the Exchange Offer
On Friday May 22, 2009, 6:37 pm EDT
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cell Genesys, Inc. (NASDAQ:CEGE - News) today announced that it has commenced an exchange offer (the “Exchange Offer”) to exchange all of the approximately $68.3 million aggregate principal amount of its outstanding 3.125% Convertible Senior Notes due November 1, 2011 (the “Existing Notes”). For each $1,000 principal amount of Existing Notes validly tendered, the holder thereof will receive (i) $500 in cash, plus accrued and unpaid interest on such $1,000 principal amount of Existing Notes, (ii) 205.8824 shares of Cell Genesys’ common stock, and (iii) $310 principal amount of Cell Genesys’ new 3.125% Convertible Senior Notes due May 1, 2013 (“New Notes”). If all holders of the Existing Notes tender into the Exchange Offer, the exchange is estimated to result in a cash expenditure of approximately $34.2 million plus approximately $0.2 million in accrued and unpaid interest, and the issuance of approximately 14.1 million new shares of common stock and approximately $21.2 million principal amount of New Notes. As of May 21, 2009, the Company had 91,809,651 shares of common stock outstanding.
A holder of approximately 67.6% of the outstanding principal amount of Existing Notes has committed to tender its Existing Notes in the Exchange Offer, subject to certain terms and conditions.
The Exchange Offer will expire at 5:00 p.m. New York City time, on Thursday, June 22, 2009, unless extended. Tenders of the Existing Notes must be made before the Exchange Offer expires and may be withdrawn at any time before the Exchange Offer expires. The Exchange Offer is conditioned upon at least 87.5% of the aggregate principal amount of the outstanding Existing Notes being validly tendered and not withdrawn. The Exchange Offer is also subject to several other conditions.
Further details about the terms, conditions, risk factors, tax considerations and other factors that should be considered in evaluating the Exchange Offer are set forth in an Offer to Exchange and a related Letter of Transmittal, which are expected to be distributed to holders of the Existing Notes beginning today.
Written materials explaining the full terms and conditions of the Exchange Offer were filed with the Securities and Exchange Commission (the “SEC”) today. The materials are available free of charge at the SEC’s website — www.sec.gov. In addition, the company will provide copies of these documents free of charge to holders of its outstanding Existing Notes upon request to the company at 650-266-3000 or from the exchange agent for the Exchange Offer, U.S. Bank National Association, at (800) 934-6802.
This news release is for informational purposes only, and is not an offer to buy or the solicitation of an offer to sell any security. The Exchange Offer is being made only pursuant to the Exchange Offer documents that are being distributed to the holders of the Existing Notes and filed with the SEC.
Hey seabiscuit,
I was wondering if I could take up some of your idle time? I have a technical question and I think your the gal that could help me. Thanks Bird
Email me at clearasglass.lance@gmail.com
This is what happens when the almighty FDA approves a drug :
http://finance.yahoo.com/q?s=VNDA
900 percent gain in the twinkling of an eye .
CEGE's drugs await the touch from the Throne ...the FDA .
Pwease , pritty pritty pwease .
Spare time on my hands ....and everyone knows what happens with idle hands .
Renee
Cell Genesys cuts Q1 loss as it winds downSan Francisco Business Times
Cell Genesys Inc. on Thursday reported a first quarter loss of $8.7 million, or 10 cents a share, narrowed from a loss in the same period last year of $22.6 million, or 29 cents a share.
South San Francisco-based Cell Genesys (NASDAQ:CEGE) said the decreased loss was primarily the result of a reduced level of operations through its restructuring plan.
The company said it continued to explore strategic alternatives, including merger with or acquisition by another company, additional restructuring, repurchase of additional amounts of convertible notes or allocation of its remaining resources toward other biopharmaceutical product areas.
Cell Genesys engaged Lazard Freres & Co LLC in connection with the evaluation of strategic alternatives.
The company already cut about 95 percent of its staff, from 290 persons to 16, by eliminating all research and development, manufacturing, clinical and regulatory activities.
The company said it expects to cut more during the next few months as additional activities are phased out or outsourced.
All major facility leases were also terminated at its head office and Hayward manufacturing facility.
In the first quarter a collaborative agreement with Takeda Pharmaceutical Co. Ltd. for GVAX immunotherapy for prostate cancer came to an end, and Cell Genesys recognized $600,000 in reimbursement revenue from Takeda.
License agreements that were terminated included those relating to the development and commercialization of oncolytic therapies with Novartis Pharma AG and certain affiliates as well as a gene activation technology license agreement with sanofi-Aventis which resulted in recognition of $100,000 in revenue.
The company recorded a restructuring charge of $2.6 million in the quarter, including $2.8 million for workforce reduction initiatives, and $3.9 million for lease termination costs partially offset by a $4.1 million non-cash gain from recognizing the deferred rent related to terminated operating leases.
All contents of this site © American City Business Journals Inc. All rights reserved
CEGE,
I am hoping that the 10% owner believes that CEGE can monetize their prostate cancer drug now that DNDN's drug has shown greater life extention.
I am hoping for some PR by the company.
Manny
CEGE need to trade min at 1$ for Nasdaq listing
CEGE, why has a 10% plus owner of CEGE bought over 2.5 million more shares in the last 2 months, 800,000 over the past week and one-half.
Check out all the Form-4's.
http://ih.advfn.com/p.php?pid=squote&symbol
well said...thanks Sea.
Nyse
Nysesp ....CEGE going higher or retracing is in the hands of whomever has taken it from .20-ish to .80-ish .
Always lock in on the way up because no public investor ever knows what ANY stock will do .
Retail investors are nothing more than pawns to the powers that control EVERY stock , so holding a core position with a trading position is the best course of action , and re-adjusting both positions as warranted .
Renee
'biscuit, you see this play moving higher or is the retrace about to begin?
thanks,
Nyse
Now at .86 . Ain't CEGE just wunnerful . EOM .
my target is 1$, CEGE went crazy when DNDN threw out the news that made it sky-rocket hundreds of percent.
I suspect they might either reactivate their cancer treatment program or maybe there is a buy-out coming? Do they have any patents or other IP that might be of interest to big player?
Very curious what's next.
I have been studying the types of stocks that can be directly influenced by message board activities in contrast to stocks that move purely on merit ( negative or positive ) .
I have observed so many stocks that run on nothing more than message board momentum ...you know , the pump and dump thingy .
CEGE had its own version of a mini pump and dump when the stock began a meteoric run a few months ago from .10/14 to over .40 .
All the higher profiled players on I-HUB were on CEGE like white on rice . DD and fundamentals meant nothing .
Then CEGE wafted back down to around .17 to .20-ish .
I wanted to survey CEGE and the stock performance without attracting too much attention to the stock , so I refrained from posting to observe CEGE without any typical message board influences .
CEGE's stock price has now risen 352 percent since the last MOMO run and drop , and purely on its own merits ....no message board players affecting the rise in PPS .
It is my affirmative assessment that CEGE will continue to outperform ....on MERIT .
Take a look and judge for oneself .
Renee
It seems so obvious with the huge increase in volume consistently now for 3 weeks something big is going to happen here
Good company with cash. I like that.
yes it must above 1.00$ for Nasdaq listing
It will be over 1.00 soon.
damn dude hit .50 too quick, it might not run that hard today
you are a good investor
cool i might give it a shot, knowing your in this this could see CTIC reborn
Nice news. I sold 40% of my shares this morning and got back my initial, I will be holding the rest for now. I have based this investment almost entirely on insider activity and it sure seems to have paid off.
a dip to .50 is it possible?
Renee, I hope CEGE does well for you and all who continue to hold. I sold today on the run up. I really do not like owning biotech stocks, so I figured I would take my profit and move on. Maybe our paths will cross again some day. GLTY
Wow. What great news!
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
889
|
Created
|
07/22/07
|
Type
|
Free
|
Moderators |
http://www.cellgenesys.com/home.shtml
http://finance.yahoo.com/q/ks?s=CEGE
http://moneycentral.msn.com/ownership?Symbol=CEGE
Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California. Feel for you folks, sincerely.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |